Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01212679 | Effects of Intranasal Nerve Growth Factor for Traumatic Brain Injury | PHASE2 | COMPLETED | 106 | — | — | Dec 1, 2010 | Oct 1, 2017 | Nov 1, 2017 | 1 | China |
Neurological functions will be assessed by GOS(Glasgow Outcome Scale), mRS(modified Rankin Scale),BI(Barthel index).
| Arm | Type | Description |
|---|---|---|
| nerve growth factor | EXPERIMENTAL | Patients who underwent TBI will be chosen to receive NGF randomly. |
| Control | PLACEBO_COMPARATOR | Patients who underwent TBI will be chosen to receive nomral saline randomly. |
| Name | Type | Description |
|---|---|---|
| nerve growth factor | DRUG | The experimental group patients will receive NGF 20ug/d intranasally for 2 weeks. |
| nomral saline | DRUG | The Placebo Comparator group patients will receive nomral saline 20ug/d intranasally for 2 weeks. |
Inclusion Criteria: Moderate to severe blunt traumatic brain injury defined as Glasgow Coma Scale(GCS) between 7 and 13. Age 18\~65 years. Admission to Jinling Hospital between 24 to 72 hours. Subjects capable of giving informed consent or have an acceptable surrogate capable of giving consent on ...